Evidence map›Paper›PMID 35739063›Full record

ReviewRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)2022

Abuse of tropicamide eye drops: review of clinical data.

Val Bellman, Anastasia Ukolova, Elena Erovichenkova, Sarah Lam, Hirsch K Srivastava, Jared Bruce, Douglass M Burgess

Open access · diamondAbstract readReview
In one paragraph

Review in Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Val BellmanDepartment of Psychiatry, University of Missouri, Kansas City, MO, USA.
Anastasia UkolovaDepartment of Psychiatry, Sechenov University, Unica Medical Center, Moscow, Russia.
Elena ErovichenkovaPhysical Medicine and Rehabilitation, University Hospital of Pisa, Italy.
Sarah LamSchool of Medicine, University of Missouri, Kansas City, MO, USA.
Hirsch K SrivastavaDepartment of Psychiatry, University of Missouri, Kansas City, MO, USA.
Jared BruceDepartment of Biomedical and Health Informatics, University of Missouri, Kansas City, MO, USA.
Douglass M BurgessDepartment of Psychiatry, University of Missouri, Kansas City, MO, USA.
University of Missouri–Kansas City · USSechenov University · RUUniversity of Missouri Health System · USUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past 15 years, the increasing nonmedical use of tropicamide ophthalmic drops has been reported in Europe, coinciding with an increase in opioid addiction and drug-related mortality. Although tropicamide is generally known as a cheap alternative to heroin in Eastern Europe, it still appears to be a relatively new phenomenon that has arisen over the last decade. A narrative review was conducted of all the relevant sources published in more than five countries between January 1, 1975 and January 10, 2021. For bibliographic accuracy, the materials published in Russian and Italian were professionally translated to English. During the preparation of this report, we were able to interview five Russian-speaking patients who injected tropicamide in the past and we discuss another case of intravenous tropicamide use. This review was acknowledged by the institutional review board of the University of Missouri-Kansas City. All patients interviewed at the Unica Medical Center consented for their clinical information to be reported in a medical publication. We analyzed data from 50+ various sources and covered a variety of drug-related issues, including information on the extent, patterns, and trends in tropicamide use, its health consequences, and other clinical findings. The information provided in this article may help providers better detect tropicamide abuse and incorporate new rehabilitation strategies into the management of these patients.

Indexed as

TropicamideEuropeHumansItalyOphthalmic SolutionsOphthalmic SolutionsTropicamide

Identifiers

PMID35739063
PMCPMC9561840
OpenAlexW4283456606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.